Financials Reviva Pharmaceuticals Holdings, Inc.
Equities
RVPH
US76152G1004
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.08 USD | +6.21% | 0.00% | -40.58% |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Capitalization 1 | 80.73 | 40.41 | 86.88 | 143.8 | 80.96 | - |
Enterprise Value (EV) 1 | 80.73 | 40.41 | 86.88 | 143.8 | 41.06 | 49.06 |
P/E ratio | -7.05 x | -4.98 x | -3.4 x | -3.12 x | -2.33 x | -2.2 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 9,232 | 13,982 | 20,443 | 27,919 | 27,919 | - |
Reference price 2 | 8.745 | 2.890 | 4.250 | 5.150 | 2.900 | 2.900 |
Announcement Date | 22/03/21 | 15/03/22 | 30/03/23 | 15/04/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | -2.435 | -10.1 | -24.31 | -39.5 | -38.95 | -44.74 | -53.25 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -3.783 | -8.516 | -24.32 | -39.24 | -37.12 | -43.34 | - |
Net income 1 | -3.783 | -8.522 | -24.34 | -39.26 | -37.12 | -43.34 | - |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -1.240 | -0.5800 | -1.250 | -1.650 | -1.243 | -1.320 | - |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 22/03/21 | 15/03/22 | 30/03/23 | 15/04/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -2.477 | -3.965 | -7.45 | -5.519 | -3.563 | -7.774 | -6.736 | -12.07 | -10.71 | -9.988 | -10.1 | -9.85 | -10.75 | -12.1 | -13.3 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -2.277 | -3.685 | -7.361 | -5.334 | -3.513 | -8.11 | -6.6 | -12.44 | -10.48 | -9.729 | -10.16 | -9.93 | -10.77 | -12.14 | -13.6 |
Net income 1 | -2.279 | -3.685 | -7.365 | -5.341 | -3.515 | -8.118 | -6.603 | -12.44 | -10.49 | -9.724 | -10.16 | -9.93 | -10.77 | -12.14 | -13.6 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1200 | -0.2200 | -0.4000 | -0.2900 | -0.1800 | -0.3800 | -0.3000 | -0.5500 | -0.4400 | -0.3500 | -0.3700 | -0.3500 | -0.3550 | -0.3800 | -0.4150 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 15/11/21 | 15/03/22 | 16/05/22 | 15/08/22 | 14/11/22 | 30/03/23 | 15/05/23 | 14/08/23 | 14/11/23 | 15/04/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | - | - | - | - | 39.9 | 31.9 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 22/03/21 | 15/03/22 | 30/03/23 | 15/04/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.58% | 80.96M | |
+0.09% | 42.86B | |
+12.26% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.65% | 25.15B | |
-23.69% | 18.63B | |
+27.33% | 12.37B | |
-4.04% | 11.92B | |
+6.84% | 11.21B |
- Stock Market
- Equities
- RVPH Stock
- Financials Reviva Pharmaceuticals Holdings, Inc.